

# WFS1 R732C — Wolframin

Arginine → Cysteine at position 732 in luminal domain. ClinVar Conflicting including monogenic diabetes, Wolfram, T2D. AlphaMissense 0.637,  $\Delta\Delta G$  -0.83. Charge loss + thiol near C733-C765 disulfide region.

## IDENTITY

Variant	R732C (p.Arginine732Cysteine)
DNA change	c.2194C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000215396
Amino acid change	Arginine (R) → Cysteine (C) — positively-charged guanidinium replaced by thiol.

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 732	<b>89.25</b> HIGH CONFIDENCE
Domain	C-terminal luminal domain (653-869)
Position context	C-terminal luminal domain · position 732 (pLDDT 89). Adjacent to C733 (in C733-C765 disulfide).
IDR flag	No — pLDDT well above 50 threshold

Position 732 sits next to C733 (3.5 Å from C765 in the inferred disulfide). Neighbors: CYS733 (2.5 Å), MET731 (2.5 Å), ASP729 (3.7 Å — partner of G728-D729 region), GLY728 (3.8 Å). The wild-type R732 is the same R732 referenced as a partner in G736R Atlas card. R732C replaces this critical arginine with a free cysteine — adjacent to C733 (which forms a disulfide with C765). The new C732 could potentially form aberrant disulfide chemistry with C733 itself, disrupting the C733-C765 disulfide entirely.  $|\Delta\Delta G|$  0.83 + AM 0.637 + multi-phenotype confirm severe consequence.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

DYNAMUT2  $\Delta\Delta G$ 

PLDDT (ALPHAFOLD)

**0.637**

am\_class: **LPath** —  
threshold > 0.564

**-0.83** kcal/

mol  
Destabilising · Job  
177992465984

**89.25**

high confidence

## CLINICAL EVIDENCE

ClinVar classification

### CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2025/09/23 00:00

Inheritance

Multi-phenotype.

WFS1 variant landscape

R732C is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- Monogenic diabetes
- Wolfram syndrome 1
- Type 2 diabetes mellitus

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G$  2–4 → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

**Category 3/4 — Most Druggable.**  $|\Delta\Delta G| = 0.83$ . AlphaMissense 0.637 + multi-phenotype confirm severe consequence.

Mechanism: loss of R732 charge + potential aberrant disulfide with C733 disrupting the C733-C765 structural disulfide. Therapeutic: site-directed at the R732-C733-C765 microregion.

R732C is one of the most dangerous R→C class variants — it sits adjacent to a structural disulfide cysteine, creating a real risk of aberrant disulfide formation that disrupts the wild-type disulfide.

